AWGLSCP
CGON icon

ABG-WTT Global Life Science Capital Partners’s CG Oncology CGON Stock Holding History

ABG-WTT Global Life Science Capital Partners’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-495,526
Closed -$12.1M – 3
2025
Q1 		$12.1M Hold
495,526
– – 31.67% 2
2024
Q4 		$14.2M Hold
495,526
– – 32.51% 2
2024
Q3 		$18.7M Sell
495,526
-419,975
-46% -$14.7M 92.93% 1
2024
Q2 		$28.9M Hold
915,501
– – 96.44% 1
2024
Q1 		$40.2M Buy
+915,501
New +$37.4M 96.81% 1

Other funds holding CGON

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ABG-WTT Global Life Science Capital Partners's CGON Position: Q2 2025 in Review

ABG-WTT Global Life Science Capital Partners sold out of CG Oncology (CGON) in Q2 2025, closing a stake of 495,526 shares — an estimated $12.1M sold.

ABG-WTT Global Life Science Capital Partners first reported a position in CGON in Q1 2024 and held it in 5 quarters. The position peaked at $40.2M in Q1 2024. 162 funds tracked by Wall St. Rank hold CGON as of Q2 2025.

  • ABG-WTT Global Life Science Capital Partners reported no remaining CG Oncology position as of Q2 2025 after selling out during the quarter.
  • ABG-WTT Global Life Science Capital Partners sold 495,526 CG Oncology shares in Q2 2025, an estimated $12.1M.
  • ABG-WTT Global Life Science Capital Partners first reported a position in CG Oncology in Q1 2024 and held it in 5 quarters.
  • ABG-WTT Global Life Science Capital Partners's CG Oncology position peaked at $40.2M in Q1 2024.
  • 162 funds tracked by Wall St. Rank held CG Oncology as of Q2 2025.

Based on ABG-WTT Global Life Science Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.